Small Molecules in the Management of Psoriasis and Psoriatic Arthritis.
| Autor: | Konakanchi VC; From the Department of DVL, RIMS, Srikakulam, Andhra Pradesh, India., Kar BR; Department of DVL, IMS and SUM Hospital, Bhubaneswar, Odisha, India., Sathishkumar D; Department of DVL, Christian Medical College, Vellore, Tamil Nadu, India., Tahiliani S; Department of Dermatology, P D Hinduja Hospital and Research Centre, Mumbai, Maharashtra, India., Parthasarathi A; Director, Anchala Skin Institute and Research Centre, Hyderabad, Telangana, India., Neema S; Department of DVL, AFMC, Pune, Maharashtra, India., Ganguly S; Department of DVL, AIIMS, Raipur, Chhattisgarh, India., Parasramani SG; Department of DVL, Leelavati Hospital, Mumbai, Maharashtra, India., Komeravelli H; Consultant Dermatologist, Hyderabad, Telangana, India., Thomas J; Senior Consultant Dermatologist, Apollo Hospitals and KK Child Trust Hospital, Chennai, Tamil Nadu, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of dermatology [Indian J Dermatol] 2024 May-Jun; Vol. 69 (3), pp. 249-255. Date of Electronic Publication: 2024 Jun 26. |
| DOI: | 10.4103/ijd.ijd_166_24 |
| Abstrakt: | Psoriasis is a common chronic, immune-mediated inflammatory skin disease associated with various comorbidities. Managing psoriasis is often challenging as the therapy is decided based on the area of the disease, associated comorbidities and impairment in quality of life, besides the patient's preference. Making progress in the development of new molecules that can be used topically or orally, effectively controlling the disease with minimal side effects and providing long-lasting remissions are the needs of the hour. Recent developments in understanding the complexities of the pathogenesis of psoriasis have resulted in the reinforcement of treatment modalities, leading to the evolution of various biologics and small-molecule inhibitors. In comparison with biologics, both patients and treating physicians prefer small molecules for various reasons such as avoiding injections and side effects that are associated with biologics biologics. Moreover small molecules are economical than biologics. Newer small molecules, both topical and oral, are promising additions to the therapeutic arsenal in the management of psoriasis in the future. Competing Interests: There are no conflicts of interest. (Copyright: © 2024 Indian Journal of Dermatology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|